Entero Healthcare Solutions Limited has informed the Exchange regarding a press release dated February 09, 2026, titled "Acquisition Update: Entero Healthcare acquires 51.5% stake in Anand Chemiceutics A leading diagnostic and MedTech solutions provider".
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare Solutions has announced the acquisition of a 51.5% controlling stake in Anand Chemiceutics, a diagnostic and MedTech solutions provider. This is a majority stake purchase, meaning Entero will have management control over the target company. The move is aimed at strengthening Entero's presence in the diagnostics and medical technology space. The acquisition was disclosed via a press release dated February 9, 2026. Financial terms of the deal were not included in the filing.
This is a growth-oriented acquisition that could expand Entero's product portfolio and market reach in diagnostics and MedTech. Investors should watch for further disclosures on deal valuation, funding, and synergy plans, which will determine the long-term effect on shareholder value.